Visiongain has launched a new pharma report ‘’Myelodysplastic Syndrome (MDS) Drugs Market Report 2020-2030’’ by Treatment (Chemotherapy, Stem Cell Transplantation, Supportive Therapy), Therapeutic Class (Anti-anemics, Hypomethylating Agents, Immunomodulatory Drugs), and Geography.

Global Myelodysplastic Syndrome (MDS) Drugs market is anticipated to grow on account of the aging population and awareness of the disease. The global Myelodysplastic Syndrome (MDS) Drugs market is anticipated to grow at a lucrative CAGR of 9.7% and anticipated to reach USD 4.5 Billion by 2030.

Myelodysplastic syndrome is triggered by one or more gene mutations that regulate blood cell growth. It is one of the most prevalent malignant hematological diseases in the U.S. that every affects five out of every 100,000 individuals annually. An estimated 60,000 people live with MDS in the U.S. and about 10,000-15,000 new cases occur annually. Clinical manifestations such as anemia, thrombocytopenia, and neutropenia may occur in patients. Chemical exposure (such as pesticides, benzene, and tobacco) and heavy metals (such as mercury and lead) can cause the onset of disease.

This market is driven by the aging population and increasing awareness of the disease. It is also anticipated that government initiatives and favorable reimbursement policies to deliver targeted treatments will boost the market growth. The MDS International Foundation is a non-profit health organization providing psychological and financing assistance for the therapy of the disease to the patients.

High therapeutic costs remain a barrier to market growth for drugs with myelodysplastic syndrome. However, in all main economies, accessible healthcare measures are being introduced, influencing the pricing strategies and reimbursement situation of manufacturers. Moreover, increasing cost-consciousness is projected to hamper premium pricing policies of companies across the globe.

Based on therapeutic class, the MDS drugs market is segmented into hypomethylating agents, immunomodulatory drugs, and anti-anemics. Immunomodulatory drugs retained the largest market share in 2018 and are anticipated to continue trend till 2030 owing to increased therapeutic acceptance and absence of generic competition.

For patients with high-risk myelodysplastic syndrome, hypomethylating agents such as Otsuka's Dacogen and Celgene's Vidaza are used as first-line treatment. This segment is predicted to experience a steep decline in market share owing to the patent expirations of both of the above-mentioned drugs, leading to the market launch of several generics.

In 2018, the U.S. dominated the global market for myelodysplastic syndrome drugs, followed by Japan and Germany, with a share of more than 40%. In the Asia Pacific region, Japan is anticipated to show the highest growth in terms of CAGR over the forecast period.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global circulating tumor cells market. Companies are also increasing their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as Accord Healthcare Ltd., Amgen

Celgene Corporation, Dr. Reddys Laboratories Limited, Otsuka Pharmaceutical Co. Ltd, and Takeda among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020–2030 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.